A novel method about the representation and discrimination of traffic state

The representation and discrimination of various traffic states play an essential role in solving traffic accidents and congestion as the foundation of traffic state prediction. However, the existing representation of the traffic state usually only considers the road congestion layer and divides the traffic state into congested and unblocked. Representation only at the congestion layer is difficult to reflect the road traffic state comprehensively. Therefore, we select three indicators from the layers of road congestion, road safety, and road stability, respectively, then utilizing K-means to cluster the traffic state. The clustering results can be regarded as a new type for the representation of a traffic state. As a result, the traffic states are divided into four classes, which comprehensively reflects the level of road congestion, safety, and stability. Using the four traffic states obtained from the clustering results as class labels, we applied a multi-layer perceptron (MLP) to classify the different traffic states, and the receiver operating characteristic (ROC) curve is assessed to verify the superiority of the classification results. Finally, a visual display of the real-time traffic state in a city’s central area was given.Safety and Security Scienc

MiRNA levels in benign and malignant breast tissue.

<p>Levels of miR-127-3p, miR-376a and miR-652 are decreased in malignant primary breast cancer when compared to benign breast tissue. Box and whisker plots show RNU6B normalized relative miRNA levels for miR-127-3p and miR-652. As an exception un-normalized Ct values are presented for miR-376a as the normalization strategy was not applicable for this particular miRNA (due to the rather low miR-376a levels in the investigated tissue samples). A two-tailed P<0.05 was considered significant (Wilcoxon rank sum test).</p

Clinico-pathological characteristics of the malignant breast cancer patients in validation cohorts A and B.

<p>ER = estrogen receptor; PR = progesterone receptor; HER2 =  human epidermal growth factor receptor 2; IDC = invasive ductal carcinoma; ILC = inv. lobular carcinoma.</p>*<p>immunoreactive score (IRS): 0–2 =  ER/PR negative; 3–12 =  ER/PR positive.</p>**<p>IHC-score: 0–1 =  HER2 negative; 2 =  positive if HER2 amplified in FISH/CISH; 3 =  HER2 positive.</p

Diagnostic potential of deregulated circulating miRNAs for benign and malignant breast tumors (cohort B).

<p>In ROC curve analysis individual circulating miRNAs were found to have discriminatory accuracy of 0.59–0.75. A panel of seven circulating miRNAs (miR-127-3p, miR-148b, miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801) discriminated between healthy women and those with benign and malignant breast tumors with an AUC of 0.81 and the discriminatory power was superior in younger women (AUC = 0.86).</p

Independent validation of seven circulating miRNAs (cohort B).

<p>Circulating miR-127-3p, miR-148b, miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levels were independently validated as being elevated in the plasma of malignant breast cancer patients compared to healthy women. Circulating miR-148b, miR-652 and miR-801 were also elevated in the plasma of women with benign breast tumors when compared to healthy individuals. A two-tailed P<0.05 was considered significant (Wilcoxon rank sum test).</p

Investigation of three new miRNA marker candidates (miR-127-3p, miR-376a and miR-652) in cohort A.

<p>Circulating miR-127-3p, miR-376a and miR-652 are present at elevated levels in the plasma of breast cancer patients when compared to healthy women. A two-tailed P<0.05 was considered significant (Wilcoxon rank sum test).</p

Additional file 3: Table S6. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

Five-year Overall Survival exemplary for 3 Subtypes subdivided into UICC stages I and IIa for patients treated at Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012. (DOCX 15 kb

Additional file 1: Table S4. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

Case frequency for subtypes along UICC stages for patients treated at Heidelberg Breast Care Unit between 01 January 2003, and 31 December 2012). (DOCX 18 kb

Patient characteristics.

<p>Patient characteristics.</p

Prevalence of deleterious variants within subgroups.

<p>Prevalence of deleterious variants within subgroups.</p